XML 34 R19.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 11 - Segment Information | 6 Months Ended
--- | ---
Sep. 30, 2025
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 11. S egment Information Segment information is prepared on the same basis used by our chief operating decision maker ("CODM"), our CEO, to assess segment performance, allocate resources, evaluate financial results, and make key operating decisions. Our four reportable segments are organized primarily by the nature of the goods and services they sell. Our CODM regularly reviews segment-level U.S. GAAP revenues and gross profit relative to forecasted and prior period amounts, as well as non-GAAP adjusted operating expense compared to budgeted amounts. Our CODM also regularly reviews non-GAAP organic revenues growth to support strategic planning and resource deployment. The following tables set forth our segment information:
Three months ended September 30, 2025 |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Clinical Genomics |  |  | Total |
Revenues (a): |  | $ | 22,107 |  |  | $ | 13,920 |  |  | $ | 13,570 |  |  | $ | 11,140 |  |  | $ | 60,737 |
Less |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation in cost of revenues |  |  | 461 |  |  |  | 66 |  |  |  | 112 |  |  |  | 152 |  |  |  | 791 |
Amortization in cost of revenues |  |  | 140 |  |  |  | 375 |  |  |  | - |  |  |  | 192 |  |  |  | 707 |
Other cost of revenues (b) |  |  | 6,636 |  |  |  | 5,350 |  |  |  | 5,223 |  |  |  | 4,699 |  |  |  | 21,908 |
Total segment cost of revenues |  |  | 7,237 |  |  |  | 5,791 |  |  |  | 5,335 |  |  |  | 5,043 |  |  |  | 23,406 |
Gross Profit (c) |  | $ | 14,870 |  |  | $ | 8,129 |  |  | $ | 8,235 |  |  | $ | 6,097 |  |  | $ | 37,331 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 32,607 |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,724 |
Nonoperating expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,725 |
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 1,999 |
Three months ended September 30, 2024 |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Clinical Genomics |  |  | Total |
Revenues (a): |  | $ | 22,205 |  |  | $ | 11,867 |  |  | $ | 12,262 |  |  | $ | 11,499 |  |  | $ | 57,833 |
Less |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation in cost of revenues |  |  | 374 |  |  |  | 40 |  |  |  | 207 |  |  |  | 283 |  |  |  | 904 |
Amortization in cost of revenues |  |  | 134 |  |  |  | 346 |  |  |  | - |  |  |  | 192 |  |  |  | 672 |
Non-cash GKE inventory step-up amortization |  |  | 454 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 454 |
Other cost of revenues (b) |  |  | 6,071 |  |  |  | 4,314 |  |  |  | 4,845 |  |  |  | 5,118 |  |  |  | 20,348 |
Total segment cost of revenues |  |  | 7,033 |  |  |  | 4,700 |  |  |  | 5,052 |  |  |  | 5,593 |  |  |  | 22,378 |
Gross Profit (c) |  | $ | 15,172 |  |  | $ | 7,167 |  |  | $ | 7,210 |  |  | $ | 5,906 |  |  | $ | 35,455 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 31,947 |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,508 |
Nonoperating (income), net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (304 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 3,812 |
Six months ended September 30, 2025 |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Clinical Genomics |  |  | Total |
Revenues (a): |  | $ | 47,517 |  |  | $ | 25,406 |  |  | $ | 25,920 |  |  | $ | 21,437 |  |  | $ | 120,280 |
Less |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation in cost of revenues |  |  | 911 |  |  |  | 155 |  |  |  | 217 |  |  |  | 318 |  |  |  | 1,601 |
Amortization in cost of revenues |  |  | 279 |  |  |  | 747 |  |  |  | - |  |  |  | 383 |  |  |  | 1,409 |
Other cost of revenues (b) |  |  | 13,291 |  |  |  | 10,069 |  |  |  | 10,426 |  |  |  | 9,214 |  |  |  | 43,000 |
Total segment cost of revenues |  |  | 14,481 |  |  |  | 10,971 |  |  |  | 10,643 |  |  |  | 9,915 |  |  |  | 46,010 |
Gross Profit (c) |  | $ | 33,036 |  |  | $ | 14,435 |  |  | $ | 15,277 |  |  | $ | 11,522 |  |  | $ | 74,270 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 66,482 |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,788 |
Nonoperating (income), net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (1,223 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 9,011 |
Six months ended September 30, 2024 |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Clinical Genomics |  |  | Total |
Revenues (a): |  | $ | 45,162 |  |  | $ | 23,875 |  |  | $ | 24,063 |  |  | $ | 22,903 |  |  | $ | 116,003 |
Less |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation in cost of revenues |  |  | 793 |  |  |  | 86 |  |  |  | 392 |  |  |  | 495 |  |  |  | 1,766 |
Amortization in cost of revenues |  |  | 245 |  |  |  | 691 |  |  |  | - |  |  |  | 383 |  |  |  | 1,319 |
Non-cash GKE inventory step-up amortization |  |  | 1,232 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 1,232 |
Other cost of revenues (b) |  |  | 12,162 |  |  |  | 7,972 |  |  |  | 9,219 |  |  |  | 9,629 |  |  |  | 38,982 |
Total segment cost of revenues |  |  | 14,432 |  |  |  | 8,749 |  |  |  | 9,611 |  |  |  | 10,507 |  |  |  | 43,299 |
Gross Profit (c) |  | $ | 30,730 |  |  | $ | 15,126 |  |  | $ | 14,452 |  |  | $ | 12,396 |  |  | $ | 72,704 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 63,616 |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,088 |
Nonoperating expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,371 |
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 7,717 |
| (a) | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
| (b) | Other segment cost of revenues for each reportable segment includes product costs, personnel costs (including stock-based compensation), and other manufacturing and overhead costs necessary to produce and sell our products and services, excluding depreciation, amortization and any non-cash inventory step-up amortization expense.
| (c) | Gross profit as presented is consistent with GAAP measurement principles and our CODM's review of segment information.
The following table sets forth inventories by reportable segment. Our CODM is not provided with and does not regularly review any other segment asset information.
|  | September 30, |  |  | March 31, |
|  | 2025 |  |  | 2025 |
Sterilization and Disinfection Control |  | $ | 6,771 |  |  | $ | 5,545 |
Biopharmaceutical Development |  |  | 5,715 |  |  |  | 4,934 |
Calibration Solutions |  |  | 6,150 |  |  |  | 5,110 |
Clinical Genomics |  |  | 9,103 |  |  |  | 9,776 |
Total inventories |  | $ | 27,739 |  |  | $ | 25,365 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration